RxDoctor Payments Data

Karen Spahr, DO

Internal Medicine · Oskaloosa, IANPI 1194891374

Payments from drug & device makers

$530in general payments, 2019–2025

Across 34 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$386
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$38
  • Novo Nordisk$32
  • Boehringer Ingelheim$30
  • AstraZeneca$27
  • Amgen$18

What the payments were for

  • Food & beverage$48692%
  • Education$448%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$530 in reported general payments places this provider in the 75th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$64,053
Medicare patients
160
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tresiba Flextouch U-200Insulin Degludec33$104,030
Breztri AerosphereBudesonide/Glycopyr/Formoterol103$70,963
OzempicSemaglutide62$61,461
XareltoRivaroxaban44$47,561
EliquisApixaban22$14,562
RybelsusSemaglutide12$11,961
TrulicityDulaglutide12$10,567
FarxigaDapagliflozin Propanediol12$9,018
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$7,679
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,690
SymbicortBudesonide/Formoterol Fumarate15$5,980
MyrbetriqMirabegron12$5,282
Albuterol Sulfate HfaAlbuterol Sulfate156$4,683
Nabumetone128$2,791
Omeprazole326$2,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere, Symbicort$27$93,640145 claims
Novo NordiskOzempic, Rybelsus$32$73,42274 claims
Boehringer IngelheimStiolto Respimat$30$6,69014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Oskaloosa

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →